Company intelligence / Profile preview

Centagen

Boulder, Colorado, United Statescentagen.com ↗

Ownership: Private
Development stage: Other

Overview

Centagen is developing proprietary nanotechnologies to deliver reprogramming factors that aim to reverse biological aging by decades. Their approach builds on the science behind Yamanaka factors and focuses on activating adult stem cells to treat age-related disorders. The company has filed patents but does not appear to have reported clinical results yet.

Therapeutic areas: Other
Modalities: NanoparticleSmall moleculeStem cell therapy
Industry: Biotech

Partnerships

None publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Centagen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Centagen.

Explore the full profile